Vascular Inflammation in Psoriasis- Apremilast Trial (VIP-A Trial)
Psoriasis is a systemic (affecting the entire body) inflammatory (causing redness, swelling, and pain) disorder and not just a disorder of the skin. Evidence has shown that psoriasis is a risk factor for developing high blood pressure, diabetes, obesity, high cholesterol, heart attack, and stroke. The purpose of this study is to assess the effects of aprelimast (Otezla), an FDA approved medication for the treatment of psoriasis on systemic inflammation and cardiovascular disease risk factors in people diagnosed with moderate to severe psoriasis.
This study will look for systemic vascular inflammation in study participants with a test called FDG-PET/CT (Fluorodeoxyglucose-positron emission tomography/computed tomography). The study will also look for cardiometabolic (heart disease and metabolic factors such as types of blood fats) identifiers in the blood. A blood sample will be taken that will look for these markers identifying high cholesterol, cholesterol efflux function (the ability of cholesterol to move in the body), metabolic factors, and inflammation. This study will also compare subject-reported outcomes with a questionnaire that will assess quality-of-life for people living with psoriasis.
Eligibility Criteria: Psoriasis for at least 6 months as diagnosed by a doctor; moderate to severe psoriasis (defined by 10% body surface area covered in psoriasis) at initial visit; weight less than or equal to 300 pounds; systolic blood pressure less than 180 mmHg and diastolic blood pressure less than 95 mmHg.
- Study Identifier: 826652
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required